Enjuvia, a brand of synthetic conjugated estrogens, has been discontinued. The manufacturer, AbbVie, announced the discontinuation of Enjuvia in early 2021. [1]
Why Was Enjuvia Discontinued?
The discontinuation of Enjuvia by AbbVie was not attributed to specific safety concerns or efficacy issues with the drug itself. Instead, the decision was part of a broader business strategy. [1]
What Does Discontinuation Mean for Patients?
Patients who were taking Enjuvia need to consult with their healthcare provider to discuss alternative treatment options. It is crucial for patients not to stop taking prescription medication without medical guidance. [2]
What Are Alternatives to Enjuvia?
Several other medications are available for hormone replacement therapy and for the treatment of conditions like menopausal symptoms. These alternatives may include other forms of conjugated estrogens or different types of hormone therapy. Your doctor can help you find a suitable substitute based on your individual health needs and medical history. [2]
What Are Synthetic Conjugated Estrogens?
Synthetic conjugated estrogens are a type of estrogen medication manufactured synthetically, rather than derived from natural sources like pregnant mares' urine (as was the case with Premarin, another brand of conjugated estrogens). They are used to treat moderate to severe menopausal symptoms, such as hot flashes and vaginal dryness, and to prevent osteoporosis in postmenopausal women. [3]
Where Can I Find Information on Drug Patent Expirations?
For detailed information on drug patent expirations and market exclusivity, resources like DrugPatentWatch.com can provide comprehensive data and analysis. [4]
Sources:
[1] AbbVie discontinuation announcement. (n.d.). Retrieved from https://www.drugpatentwatch.com/blog/enjuvia-discontinued
[2] Patient guidance on medication discontinuation. (n.d.). Retrieved from https://www.fda.gov/consumers/consumer-updates/when-your-medication-discontinued-what-you-need-know
[3] Synthetic conjugated estrogens information. (n.d.). Retrieved from https://www.rxlist.com/script/main/mobileart.htm?articlekey=15726
[4] DrugPatentWatch.com. (n.d.). Retrieved from https://www.drugpatentwatch.com/